Letycja Róg

Dr. Letycja Róg


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Letycja RógLetycja Róg
Letycja Róg
JZJacek Piotr Zawierucha
Jacek Piotr Zawierucha
BSBartosz Symonides
Bartosz Symonides
WMWojciech Marcinkowski
Wojciech Marcinkowski
SMSławomir Jerzy Małyszko
Sławomir Jerzy Małyszko
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background: The overall incidence of malignancy in patients with end-stage kidney disease (ESKD) is reportedly higher compared to the general population. Cancer remains one of the dominant causes of death in these patients, due in part to uremia-induced impairment of tumor immune surveillance. Malignancy is one of the major limitations in the evaluation of potential kidney transplantation. This study aimed to assess the prevalence of cancer in hemodialysis population, particularly in relation to the waiting list. Materials and Methods: From the population of 5879 prevalent hemodialysis patients (60% men), 757 of them had a history of malignancy. In this population, 449 patients were actively waitlisted, and 4619 were not considered for potential kidney transplantation. Only 54 patients had unclear status in relation to active waiting list (during evaluation/disqualification). We assessed demographic data, basal biochemical data, and comorbidities, including malignancy, in relation to age, sex, presence of metastasis, and being actively waitlisted. Results: Malignancy was reported in 13% of hemodialysis patients, 6% of which had metastatic disease. Patients with malignancy were older (p < 0.001). More cases of cancer were observed in males (p = 0.02), who also had higher Charlson Comorbidity Index scores. Moreover, in patients with cancer, cardiovascular diseases were more common. They were also more malnourished (lower albumin, hemoglobin, lean mass) and more inflamed (higher ferritin, lower phosphorus). Only 27 patients with cancer were actively waitlisted, representing only 3.8% of this population. Patients with prior cancer on the active waiting list constituted 6% of all the waitlisted patients. Patients with a history of malignancy on the active waiting list were significantly younger, healthier, with significantly lower Charlson Comorbidity Index score, significantly lower ferritin, lower prevalence of diabetes, and higher blood pressure when compared to patients with malignancy who not listed for kidney transplantation. Conclusions: As malignancy became a more common comorbidity in dialysis patients, the elderly in particular, standardized cancer screening protocols should be promoted in dialysis units. Modern oncology has made huge progress, enabling the treatment of previously incurable cancers, as malignancy after kidney transplantation is considerably increased either due to de novo cancers or the recurrence of previous malignancy. Therefore, the evaluation of potential kidney transplant recipients, with tailored cancer screening and multidisciplinary evaluation, is strongly recommended. Besides a history of malignancy, the cardiovascular status also determines the eligibility for transplantation in dialysis patients. It is of paramount importance as the main cause of death in transplant recipients is cardiovascular death followed by malignancy.

9 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
EDEwelina Dziąg-Dudek
Ewelina Dziąg-Dudek
ASAleksandra Semeniuk-Wojtaś
Aleksandra Semeniuk-Wojtaś
MMMagdalena Modzelewska
Magdalena Modzelewska
ALArkadiusz Lubas
Arkadiusz Lubas
Letycja RógLetycja Róg
Letycja Róg
RSRafał Stec
Rafał Stec
Background/Objectives: In recent years, growing evidence that the tumor microenvironment (TME) plays crucial roles in the progression and treatment responses of various cancers has emerged. Unfortunately, we still do not fully understand the mechanisms through which the TME influences cancer development. Therefore, the aim of this study is to assess the impact of the TME on the clinical course of the disease, comparing primary and metastatic tumors. Materials and Methods: This retrospective study included 30 colorectal cancer patients for which tissue samples from primary and metastatic tumors were available for immunohistochemistry. A multiple Cox proportional hazards regression analysis was performed to characterize differences between the microenvironments of primary and metastatic tumors, as well as between lesions diagnosed at different times after resection. Results: Immune cell infiltration was higher in metastatic than primary tumors. Statistically significant differences were observed only in the central part of the tumor, while cell infiltration at the periphery had no prognostic significance. In the multivariate analysis, a positive correlation was revealed between the expression of Programmed Death-Ligand 1 (PD-L1) on primary tumor cells (TCs) and survival (HR: 5.43; 95% CI: 1.89–15.61; p = 0.0017). Conclusions: Primary and metastatic tumors differ regarding their tumor microenvironment. As such, the tumor immune status should be considered as a key factor when selecting a therapeutic strategy, as well as for post-treatment surveillance.

4 July 2025 in Oncology in Clinical Practice
Verified
Journal Article
Open access
PDF file
Letycja RógLetycja Róg
Letycja Róg
MPMichał Pyrża
Michał Pyrża
PPPaweł Pihowicz
Paweł Pihowicz
APAgnieszka Perkowska-Ptasińska
Agnieszka Perkowska-Ptasińska
JMJolanta Małyszko
Jolanta Małyszko
Not available Keywords: pancreatic adenocarcinoma gemcitabine hemolytic — uremic syndrome kidney biopsy acute kidney injury

Verified
Journal Article
Open access
PDF file
Letycja RógLetycja Róg
Letycja Róg
MPMichał Marcin Pyrża
Michał Marcin Pyrża
EWEwa Izabela Wojtaszek
Ewa Izabela Wojtaszek
TGTomasz Głogowski
Tomasz Głogowski
AKAleksandra Kaszyńska
Aleksandra Kaszyńska
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background: Renal cell carcinoma (RCC) accounts for nearly 90% of kidney cancers. Transplantation is the best treatment for kidney failure, associated with improved survival, quality of life, and lower societal costs compared with remaining on dialysis. Thanks to modern immunosuppression, rejection rates have decreased. Cancer is the second most common cause of morbidity and mortality in kidney transplant recipients (KTRs) after cardiovascular disease. KTRs are at increased cancer risk due to chronic immunosuppression. Case report: We report a 54-year-old kidney transplant recipient without prior history of malignancy who developed metachronous bilateral RCC early posttransplant (first RCC within 3 months after kidney transplantation and second RCC after one year later). Both tumours were treated with nephrectomy. Conclusions: Early diagnosis enabled appropriate oncologic management while preserving graft function. It should also be stressed that beside graft assessment, abdominal sonography should not be forgotten in kidney allograft recipients, in particular, in certain high-risk patients (i.e., elderly, male, with longer dialysis vintage, smokers, obese, with high burden of immunosuppression including pretransplant immunosuppressive therapy, induction at transplantation, etc.).